Ventricular hypertrophy and hypertension: prognostic elements and implications for management.

Area of Science:

• Cardiology
• Hypertension Research
• Internal Medicine

Background:

• Left ventricular hypertrophy (LVH) is a significant independent predictor of adverse cardiovascular outcomes, including stroke, coronary heart disease, and sudden cardiac death.
• Hypertension is a primary driver for the development of LVH, contributing to its multifactorial prognostic power.
• LVH signifies both the cumulative effects of risk factors and intrinsic pathological cardiac changes.

Purpose of the Study:

• To review the role of Angiotensin II in the pathogenesis of LVH.
• To evaluate the efficacy of antihypertensive treatments, particularly Angiotensin II Receptor Blockers (ARBs), in reversing LVH.
• To assess the impact of these treatments on cardiovascular outcomes independent of blood pressure reduction.

Main Methods:

• Review of existing literature on LVH, hypertension, and cardiovascular outcomes.
• Analysis of studies investigating the effects of specific antihypertensive agents on cardiac structure and function.
• Evaluation of clinical trial data on ARBs and their impact on LVH and cardiovascular events.

Main Results:

• Angiotensin II is identified as a key mediator in the development of LVH.
• Certain antihypertensive therapies, notably ARBs, demonstrate the ability to reverse LVH.
• These beneficial effects on LVH and cardiovascular outcomes are observed independently of significant blood pressure reduction.

Conclusions:

• LVH is a critical risk factor for cardiovascular morbidity and mortality.
• Targeting the renin-angiotensin system, especially with ARBs, offers a promising therapeutic strategy for LVH.
• Further research is needed to establish ARBs as a first-line treatment for hypertensive patients with LVH.